EP3843751

COMBINATION PRODUCT OF A BCL-2/BCL-XL INHIBITOR AND A CHEMOTHERAPEUTIC AGENT AND USE THEREOF IN THE PREVENTION AND/OR TREATMENT OF DISEASES

  • Status:
    EP einkaleyfi: Þýðing ekki lögð inn
  • EP appl. date:
    30.7.2020
  • EP published:
    27.3.2024
  • EP application number:
    20847777.8
  • Max expiry date:
    29.7.2040
  • Title in English:
    COMBINATION PRODUCT OF A BCL-2/BCL-XL INHIBITOR AND A CHEMOTHERAPEUTIC AGENT AND USE THEREOF IN THE PREVENTION AND/OR TREATMENT OF DISEASES
  • Language of the patent:
    English

Timeline

Today
30.7.2020EP application
27.3.2024EP Publication

Owner

  • Name:
    Ascentage Pharma (Suzhou) Co., Ltd.
  • Address:
    Unit 701, Building B7, 218 Xinghu Street Suzhou Industrial Park, Suzhou, Jiangsu 215000, CN
  • Name:
    Ascentage Pharma Group Corp Limited
  • Address:
    9/F, Wah Yuen Building 149 Queen's Road Central, Hong Kong, HK

Inventor

  • Name:
    YANG, Dajun
  • Address:
    Suzhou, Jiangsu 215000, CN
  • Name:
    ZHAI, Yifan
  • Address:
    Suzhou, Jiangsu 215000, CN
  • Name:
    FANG, Douglas Dong
  • Address:
    Suzhou, Jiangsu 215000, CN
  • Name:
    TANG, Qiuqiong
  • Address:
    Suzhou, Jiangsu 215000, CN

Priority

  • Number:
    PCT/CN2019/098625
  • Date:
    31.7.2019
  • Country:
    WO
  • Number:
    202010631089
  • Date:
    3.7.2020
  • Country:
    CN

Classification

  • Categories:
    A61K 31/496, A61K 31/55, A61P 35/00, A61P 35/02, A61P 35/04

Upload documents